5Y Capital

Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.

Triastek Co. Ltd. manufactures 3D printed pharmaceuticals and related medical equipment. It offers blockbuster drugs, orphan drugs, and complex drug delivery technologies. It also offers drug 3D printing, such as three-dimensional drug structure formulation design, 3D printing pharmaceutical equipment, and drug product development methods for patent families in China, US, Europe, and Japan. The company also owns Melt Extrusion Deposition (MED), a 3D printing technology universally applicable to solid formulations. The company was founded in 2015 and is based in Nanjing, China.

Adjuvance Technologies, Inc. is a biopharmaceutical company based in Lincoln, Nebraska, founded in 2009. The company specializes in the design and manufacture of adjuvant molecule vaccines, which enhance the immune response in vaccination. Its product offerings include Saponex, a synthetic version of the naturally occurring adjuvant QS-21; TQL1055, a synthesized novel analogue; and Triterpene Saponin Synthesis Technology (TriSST), which focuses on the synthesis of novel compositions. Additionally, Adjuvance provides TiterQuil, a collection of unique molecules that do not occur in nature. Through its innovative approach, Adjuvance Technologies aims to advance vaccine efficacy and contribute to public health.

Redesign Science Inc is a biotechnology company based in New York, established in 2017, that specializes in small molecule drug discovery. The company employs advanced techniques, including first-principles physics and artificial intelligence, to simulate protein targets at the atomic level. This approach allows Redesign Science to identify subtle drug opportunities that conventional computational models may overlook. By focusing on the development of first-in-class small molecules, the company aims to address emerging and challenging targets associated with significant unmet medical needs. Their innovative methodologies not only enhance the understanding of biological pathways and disease mechanisms but also drive the commercialization of new therapeutic solutions.

Allysta Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic peptides for eye diseases. The company’s products include ALY688 for treatment of inflammatory ocular surface disorders. It develops medicines for dry eye disease and liver disease. Allysta Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Belmont, California.

Triastek Co. Ltd. manufactures 3D printed pharmaceuticals and related medical equipment. It offers blockbuster drugs, orphan drugs, and complex drug delivery technologies. It also offers drug 3D printing, such as three-dimensional drug structure formulation design, 3D printing pharmaceutical equipment, and drug product development methods for patent families in China, US, Europe, and Japan. The company also owns Melt Extrusion Deposition (MED), a 3D printing technology universally applicable to solid formulations. The company was founded in 2015 and is based in Nanjing, China.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs. It seeks to solve challenges in health with science, to help people live healthier and longer lives. It works directly with the scientists, clinicians, and health professionals around the world to identify and develop the natural compounds. Its product is a proprietary formulation of two ingredients designed to support long-term well-being at the cellular level.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.

ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.

Luqa Pharmaceuticals Co., Ltd. is a specialty pharmaceutical company based in Hong Kong that focuses on the Chinese market. Established in 2010, the company is engaged in the acquisition, development, and commercialization of innovative healthcare products aimed at improving patient quality of life. Its product portfolio includes dermatological and aesthetic treatments such as Ebernet, an eberconazole cream for fungal skin infections, and Strataderm, a silicone gel for scar treatment and prevention. Additionally, Luqa offers gastrointestinal and oral care products like Lacteol, a probiotic formulation, and GelX, a medical device for oral cavity lesions. Other products include GelX Xero for dry mouth relief, Aftacure for oral mucosal lesions, Ialuxid Gel for post-surgical wounds, and Podofilm for benign epithelial formations. Luqa Pharmaceuticals supplies its products to prescribers, healthcare providers, and patients across China, Hong Kong, and Macau.

ASLAN Pharmaceuticals is a clinical-stage biopharmaceutical company based in Singapore, specializing in immunology and oncology. Founded in 2010, the company focuses on developing innovative treatments aimed at improving patient outcomes. Its clinical portfolio includes ASLAN004, a monoclonal antibody therapy for atopic dermatitis and other immunological conditions, as well as small molecule inhibitors targeting various cancer types. ASLAN collaborates with notable partners such as Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited to enhance its research and development efforts. The company is dedicated to creating novel medicines for both Asian and global markets.

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.

Indel Therapeutics Inc. is a Vancouver‐based biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs focused on curing difficult‐to‐treat and hospital‐acquired infections. These programs are based on Indel's paradigm‐changing antimicrobial drug discovery platform, a patented technology that that has opened a rich, new area of antimicrobial drug targets for the treatment of infectious diseases and has the potential to provide an advantage against drug resistance.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.

Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

Inimex Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of innate defense regulators (IDRs) that modulate the body's innate defenses without causing inflammation. The company offers IMX942, an IDR product that improves survival, ameliorate tissue damage, and reduce bacterial infections through modulation of innate defenses. Its products are used to treat infections and conditions involving tissue injury; ventilator associated pneumonia, tracheobronchitis, bacteremia, endocarditis, and mucositis; and cancer diseases. Inimex Pharmaceuticals Inc. was founded in 2001 and is headquartered in Burnaby, Canada.

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.